Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Peripheral neuropathy can be caused by a variety of systemic diseases, toxic exposures, medications, infections, and hereditary disorders. The most common causes include diabetes, hypothyroidism, and nutritional de?ciencies. Peripheral neuropathy can either be inherited or developed due to injury or illness.

The global peripheral neuropathy treatment market is estimated to be valued at US$ 1,685.7 million in 2020 and is expected to exhibit a CAGR of 3.6% during the forecast period (2020-2027).

Figure 1. Global Peripheral Neuropathy Treatment Market Share (%), by Region, 2020

Peripheral Neuropathy Treatment  | Coherent Market Insights

Drug approvals by the major players is expected to propel growth of the global peripheral neuropathy treatment market.

Major players are focusing on developing drugs for the treatment of peripheral neuropathy, which is expected to boost the market growth during the forecast period. For instance, in June 2020, Novaremed AG a clinical-stage Switzerland-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) clearance on an investigational new drug (IND) application to initiate its US-based Phase II clinical study of the novel drug candidate, NRD135S.E1, for the treatment of painful diabetic peripheral neuropathy (PDPN).

request-sample

Peripheral Neuropathy Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 1,685.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.6% 2027 Value Projection: US$ 2,155.0 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, Others.
  • By Treatment:
    • Pharmacological Therapies: Pain Relievers, Anti-seizure Medications, Antidepressants.
    • Non-pharmacological Therapies: Transcutaneous Electrical Nerve Stimulation, Plasma Exchange and Intravenous Immune Globulin, Others.
  • By Distribution Channel: Hospitals and Clinics, Ambulatory Centers, Others.
Companies covered:

Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddy's Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd.

Growth Drivers:
  • Increasing geriatric population
  • Rising cases of diabetics and cancer cases
  • Novel drug approvals and launches
Restraints & Challenges:
  • Side effects of drugs

Figure 2. Global Peripheral Neuropathy Treatment Market Share (%), by Type, 2020

Peripheral Neuropathy Treatment  | Coherent Market Insights

Rising diabetic and cancer cases in North America are expected to boost the market growth

North America is expected to hold dominant position in the global peripheral neuropathy treatment market, owing to increasing prevalence of diabetes and cancer in the region. For instance, according to the American Diabetes Association, in 2018, around 34.2 million people in the U.S. (representing 10.5% of the total U.S. population) suffered from diabetes. Moreover, according to the National Cancer Institute, 2016, around 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from the disease. The same source also states that, the number of people with cancer is expected to rise to 19 million by 2024 in the U.S.

Global Peripheral Neuropathy Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and resulting lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector, which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the pandemic has hampered the development, production, and supply of drugs and other healthcare products, and also affected growth of healthcare businesses across the globe.

As a result, the COVID-19 pandemic is expected to limit growth of the global peripheral neuropathy treatment market during the forecast period.

Key Players

Major players operating in the global peripheral neuropathy treatment market include Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddy's Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd. among others.

Peripheral neuropathy is a disorder that affects the peripheral nerves. Peripheral neuropathy has a variety of systemic, metabolic, and toxic causes, for instance diabetes in metabolic cause. The most common treatable causes include diabetes mellitus, hypothyroidism, and nutritional deficiencies. The diagnosis require careful clinical assessment, judicious laboratory testing, and electro diagnostic studies or nerve biopsy, if the diagnosis remains unclear.  

Market Dynamics

Rising aging population is expected to drive the global peripheral neuropathy treatment market growth. For instance, according to an article published by the World Health Organization (WHO) in February 2018, reports that between 2015 and 2050, the proportion of the worldwide geriatric population will nearly double from 12% to 22%.

Moreover, rising diabetic cases is expected to drive the market growth. For instance, according to an article published by the International Diabetes Federation (IDF), in 2017, the estimated number of 18 to 99 year old diabetic patients was around 425 million globally.

Key features of the study:

  • This report provides in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global peripheral neuropathy treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddy's Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd, among others.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.

Detailed Segmentation:

  • Global Peripheral Neuropathy Treatment Market, By Type:
    • Diabetic Peripheral Neuropathy
    • Chemotherapy-induced Peripheral Neuropathy
    • Idiopathic Peripheral Neuropathy
    • Others
  • Global Peripheral Neuropathy Treatment Market, By Treatment:
    • Pharmacological Therapies
      • Pain Relievers
      • Anti-seizure Medications
      • Antidepressants
    • Non-pharmacological Therapies
      • Transcutaneous Electrical Nerve Stimulation
      • Plasma Exchange and Intravenous Immune Globulin
      • Others
  • Global Peripheral Neuropathy Treatment Market, By Distribution Channel:
    • Hospitals and Clinics
    • Ambulatory Centers
    • Others
  • Global Peripheral Neuropathy Treatment Market, By Region:
    • North America
      • By Type:
        • Diabetic Peripheral Neuropathy
        • Chemotherapy-induced Peripheral Neuropathy
        • Idiopathic Peripheral Neuropathy
        • Others
      • By Treatment:
        • Pharmacological Therapies
          • Pain Relievers
          • Anti-seizure Medications
          • Antidepressants
        • Non-pharmacological Therapies
          • Transcutaneous Electrical Nerve Stimulation
          • Plasma Exchange and Intravenous Immune Globulin
          • Others
      •  By Distribution Channel:
        • Hospitals and Clinics
        • Ambulatory Centers
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Type:
        • Diabetic Peripheral Neuropathy
        • Chemotherapy-induced Peripheral Neuropathy
        • Idiopathic Peripheral Neuropathy
        • Others
      • By Treatment:
        • Pharmacological Therapies
          • Pain Relievers
          • Anti-seizure Medications
          • Antidepressants
        • Non-pharmacological Therapies
          • Transcutaneous Electrical Nerve Stimulation
          • Plasma Exchange and Intravenous Immune Globulin
          • Others
      •  By Distribution Channel:
        • Hospitals and Clinics
        • Ambulatory Centers
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type:
        • Diabetic Peripheral Neuropathy
        • Chemotherapy-induced Peripheral Neuropathy
        • Idiopathic Peripheral Neuropathy
        • Others
      • By Treatment:
        • Pharmacological Therapies
          • Pain Relievers
          • Anti-seizure Medications
          • Antidepressants
        • Non-pharmacological Therapies
          • Transcutaneous Electrical Nerve Stimulation
          • Plasma Exchange and Intravenous Immune Globulin
          • Others
      • By Distribution Channel:
        • Hospitals and Clinics
        • Ambulatory Centers
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type:
        • Diabetic Peripheral Neuropathy
        • Chemotherapy-induced Peripheral Neuropathy
        • Idiopathic Peripheral Neuropathy
        • Others
      • By Treatment:
        • Pharmacological Therapies
          • Pain Relievers
          • Anti-seizure Medications
          • Antidepressants
        • Non-pharmacological Therapies
          • Transcutaneous Electrical Nerve Stimulation
          • Plasma Exchange and Intravenous Immune Globulin
          • Others
      • By Distribution Channel:
        • Hospitals and Clinics
        • Ambulatory Centers
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type:
        • Diabetic Peripheral Neuropathy
        • Chemotherapy-induced Peripheral Neuropathy
        • Idiopathic Peripheral Neuropathy
        • Others
      • By Treatment:
        • Pharmacological Therapies
          • Pain Relievers
          • Anti-seizure Medications
          • Antidepressants
        • Non-pharmacological Therapies
          • Transcutaneous Electrical Nerve Stimulation
          • Plasma Exchange and Intravenous Immune Globulin
          • Others
      • By Distribution Channel:
        • Hospitals and Clinics
        • Ambulatory Centers
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Type:
        • Diabetic Peripheral Neuropathy
        • Chemotherapy-induced Peripheral Neuropathy
        • Idiopathic Peripheral Neuropathy
        • Others
      • By Treatment:
        • Pharmacological Therapies
          • Pain Relievers
          • Anti-seizure Medications
          • Antidepressants
        • Non-pharmacological Therapies
          • Transcutaneous Electrical Nerve Stimulation
          • Plasma Exchange and Intravenous Immune Globulin
          • Others
      • By Distribution Channel:
        • Hospitals and Clinics
        • Ambulatory Centers
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Abbott*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bristol Myers Squibb
    • Cipla Limited
    • Eli Lilly and Company
    • GlaxoSmithKline plc.
    • Lupin Limited
    • Merck and Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Reddy's Laboratories
    • Mylan NV
    • Johnson & Johnson Services Inc.
    • Teva Pharmaceutical Industries Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Treatment
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • Reimbursement Scenario
    • Epidemiology
    • Pest Analysis
    • Regulatory Scenario
    • New Product Launches
    • Collaborations and Agreements
    • Market Trends
  4. Global Peripheral Neuropathy Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
    • COVID-19 Market Scenario
    • Impact of COVID-19 Market on the Peripheral Neuropathy Treatment Products
  5. Global Peripheral Neuropathy Treatment Market, By Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Diabetic Peripheral Neuropathy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Chemotherapy-induced Peripheral Neuropathy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Idiopathic Peripheral Neuropathy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Peripheral Neuropathy Treatment Market, By Treatment, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pharmacological Therapies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Pain Relievers
        • Anti-seizure Medications
        • Antidepressants
      • Non-pharmacological Therapies
        • Introduction
        • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
          • Transcutaneous Electrical Nerve Stimulation
          • Plasma Exchange and Intravenous Immune Globulin
          • Others
  7. Global Peripheral Neuropathy Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals and Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ambulatory Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Peripheral Neuropathy Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Abbott
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bristol Myers Squibb
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cipla Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GlaxoSmithKline plc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lupin Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck and Co. Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Reddy's Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan NV
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson Services Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  10. Analyst Views
  11. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 48 market data tables and 340figures on "Peripheral Neuropathy Treatment Market” - Global forecast to 2027

Frequently Asked Questions

The global peripheral neuropathy treatment market is expected to exhibit a CAGR of 3.6% during the forecast period (2020-2027).
The global peripheral neuropathy treatment market is estimated to be valued at US$ 1,685.7 million in 2020.
Increasing geriatric population, rising cases of diabetics and cancer cases, novel drug approvals and launches in the field of peripheral neuropathy treatment are favoring the market growth.
The diabetic peripheral neuropathy segment is expected to be leading segment on the basis of type in the global peripheral neuropathy treatment market during the forecast period (2020-2027).
North America peripheral neuropathy treatment market is expected to account for highest revenue share during the forecast period.
Major players operating in the global peripheral neuropathy treatment market include Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddy's Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd. among others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner